Skip to content
Buy This GLP
← Research
Evidence

Is a GLP-1 Worth the Cost? What the Economic Studies Measured

Economic studies of GLP-1 treatment reach different conclusions depending on the alternative, how long people stay on treatment, and which costs the study counts.

Editorial profile: Carla MedinaBuy This GLP Editorial Team10 min read

A 2024 systematic review examined seven studies of semaglutide’s cost-effectiveness. If you’re budgeting for treatment, the monthly cost guide explains what providers include in their published prices. The review answered a different question, comparing costs and health outcomes across treatments[1].

What the review found

Semaglutide produced more quality-adjusted life years than the comparator anti-obesity drugs — phentermine-topiramate, phentermine, and naltrexone-bupropion — and it cost more, with the incremental cost-effectiveness ratio exceeding the willingness-to-pay threshold in some cases. Against diet and exercise, and against liraglutide, it came out cost-effective. Against sleeve gastrectomy, endoscopic sleeve gastroplasty and gastric bypass, it did not.

In one model summarized by the review, estimated lifetime costs for a population with class I obesity (BMI 33) were lifestyle intervention at $124,195, endoscopic sleeve gastroplasty at $126,732, sleeve gastrectomy at $139,971, and semaglutide at $370,776[1].

The number the review does not give

A systematic review pools conclusions rather than ratios, so it is worth reading one of the underlying models directly. A 30-year Markov model from a US third-party payer perspective estimated that semaglutide 2.4 mg improved QALYs by 0.138 to 0.925 against its comparators, at a cost of $3,254 to $25,086 more. That puts the incremental cost at $23,556 to $144,296 per QALY gained [2]. Against a willingness-to-pay threshold of $150,000 per QALY, that is cost-effective against every comparator it tested — and the top of the range clears the bar by under six thousand dollars.

Two caveats belong with it. The model’s own sensitivity analysis named treatment duration, what happens after discontinuation, and weight-rebound rates as the key drivers of the result. Which is to say the answer depends most on the things nobody can promise. The study was funded by Novo Nordisk and included authors affiliated with the company. The sponsor was involved in the study design, the interpretation of the data, the writing and the decision to submit. That does not make the arithmetic wrong; it means the reader should know whose model it is.

Why surgery wins on this measure and not on every measure

A bariatric operation is a large cost once. A GLP-1 is a smaller cost indefinitely, and indefinitely is the word doing the work — a drug taken for life accumulates past a one-time procedure at some point, and these models find that point. That is an argument about money over decades, not about which is right for a particular person, and it says nothing about risk, recovery, reversibility or preference.

Cost-effectiveness estimates depend on how long people stay on treatment. A review of real-world treatment persistence found that about one in three patients in obesity cohorts without diabetes were still taking a GLP-1 at one year. A separate review of weight regain after stopping treatment shows why a model’s assumptions about what happens after withdrawal also matter.

Cost per person who actually responds

Cost per prescription is the wrong denominator, because a prescription that does not work still costs the full amount. A UK analysis divided annual pharmacy cost by the share of patients reaching a composite target, which produces a cost per patient who actually responds[3]. At the strictest target — HbA1c at or below 6.5%, weight loss of 15% or more, and no hypoglycemia — tirzepatide came in £5,650 to £9,462 lower per patient reaching it than semaglutide. The gap widened as the targets got stricter, and reversed at the loosest one, where semaglutide cost less per responder.

The analysis used a post hoc comparison from SURPASS-2 in adults with type 2 diabetes. Both groups took metformin, and the comparator was semaglutide 1 mg. The cost-per-responder analysis explains how the composite targets change the estimate. The study did not estimate cost per responder against semaglutide 2.4 mg in a weight-management population.

What a prevented heart event costs

The cardiovascular case has a number attached to it. A meta-analysis pooled 21 randomized trials and 99,599 patients across eight GLP-1 drugs. Over a mean 2.4 years, major adverse cardiovascular events fell, with an incidence rate ratio of 0.87 (95% CI 0.83 to 0.91) and a number needed to treat of 66[4]. All-cause death gave an NNT of 121, cardiovascular death 170, and the authors rated the evidence for these reductions as high certainty. Compared with control groups, gastrointestinal disorders were 63% more frequent and gallbladder disorders were 26% more frequent.

Does it pay for itself?

An analysis of the US Medical Expenditure Panel Survey included 7,144 person-years from 2019 and 2021, of which 275 represented sustained GLP-1 use. It found non-drug medical spending lower by $2,586 per person-year among users and acute-care spending lower by $2,019 [5]. With medication included, estimated total spending was $6,483 higher per person-year among sustained users. These are adjusted associations from survey data and cover spending within the same year.

A 30-year model in China compared liraglutide plus metformin with sitagliptin plus metformin for adults whose type 2 diabetes was inadequately controlled on metformin alone. It estimated an additional cost of 267,985.96 RMB per quality-adjusted life year. At the study’s threshold of 298,995 RMB per quality-adjusted life year, liraglutide plus metformin was cost-effective in 63.6% of the simulations[6].

What this changes at the checkout

In our pricing records, monthly semaglutide prices range from $60 to$1,299 across 158 sellers. Use the guide to advertised and billed prices to check whether your quote includes care fees and when the renewal price starts. Use the continuing charge when you estimate costs beyond the first fill.

Enter your monthly charge and any upfront fee in the cost calculator to estimate what you would spend over the treatment period you’re considering. Confirm the renewal price and billing interval with the provider.

Price figures are computed from this site’s own records at build time, most recently read November 2026. The studies use different methods, including economic models and observational survey data.

Frequently asked

Is semaglutide cost-effective?
It depends on the comparator. The review found it cost-effective against diet and exercise and against liraglutide, and not cost-effective against sleeve gastrectomy, endoscopic sleeve gastroplasty or gastric bypass.
Is $370,776 what it costs?
No. That is a modeled lifetime cost for a class I obesity population including downstream care, sitting alongside $124,195 for lifestyle intervention and $139,971 for sleeve gastrectomy in the same model.
What is the cost per QALY?
One 30-year model put it at $23,556 to $144,296 per QALY gained against its comparators, under a willingness-to-pay threshold of $150,000. The study was funded by the manufacturer.
Does stopping early change the economics?
Treatment duration and weight regain after stopping can change a model’s cost-effectiveness estimate. The effect depends on the assumptions the model uses.
Does a GLP-1 pay for itself in reduced medical costs?
In one US survey analysis, sustained use was associated with $2,586 less in non-drug medical spending and $2,019 less in acute-care spending per person-year. Total medical spending was $6,483 higher in the same analysis.
How many people have to take it to prevent one heart event?
Across 21 trials with 99,599 participants, the estimated number needed to treat to prevent one major cardiovascular event was 66 over an average of 2.4 years. The estimate depends on baseline risk and the length of follow-up.

Sources

  1. [1] Asiabar AS, et al. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review European Journal of Clinical Pharmacology. PMID 39254692
  2. [2] Kim N, et al. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States Journal of Managed Care & Specialty Pharmacy. PMID 35737858
  3. [3] Kanumilli N, Osumili B, Evans J, Webb J, et al. (2026). Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK Journal of Medical Economics. PMID 41771166
  4. [4] Galli M, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Journal of the American College of Cardiology. PMID 40892610
  5. [5] Çelebi O, et al. (2026). GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis Healthcare. PMID 42588330
  6. [6] Yang F, et al. (2026). Economic evaluation of liraglutide versus sitagliptin in the treatment of type 2 diabetes mellitus inadequately controlled with metformin Frontiers in Clinical Diabetes and Healthcare. PMID 42630210

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence